MPS World Summit 2026
Walter E. Washington Convention Center, Washington, DC
May 26, 2026 - May 29, 2026The MPS World Summit gathers a global community of researchers, innovators, and regulatory experts advancing next‑generation microphysiological systems and organ‑on‑chip technologies. Join us at booth #119 and attend our satellite meeting, presentation, and poster sessions to learn about our patient-derived organoid models and HepatoXcell™ primary human hepatocytes. If you would like to speak to one of ATCC’s representatives about a product or service, please contact us so we can discuss your needs.
Join our satellite meeting Attend our presentation Check out our posters Contact us
Join our Satellite Meeting
Standardizing Organoids for Tomorrow: A Collaborative Approach to Scalability and Access
Date: Monday, May 25, 2026 | Time: 6:00 – 8:00 PM | Location: Walter E. Washington Convention Center (Room 201)
Appetizers, wine, and beer provided for attendees
Join ATCC and global leaders from academia, industry, and regulatory communities for a solutions-oriented discussion on how to address the urgent need for a coordinated approach to organoid manufacturing, preservation, standardization, and distribution. Through presentations and a panel discussion with esteemed experts, we’ll discuss challenges in scalability, reproducibility, and regulatory alignment to deliver actionable strategies that accelerate global access to high-quality organoid-based models.
Thomas Hartung, MD, PhD
Professor; Director, Center for Alternatives to Animal Testing
Johns Hopkins Bloomberg School of Public Health; Whiting School of Engineering; Georgetown University; University of Konstanz
Magdalena Kasendra, PhD
Director of Research & Development, Center for Stem Cell and Organoid Medicine
Cincinnati Children’s Hospital Medical Center
Srivatsan (Sri) Kidambi, PhD
Director, NIH Standardized Organoid Modeling Center
National Institutes of Health
Carolina Lucchesi, PhD
Principal Scientist, Head of Microphysiological Systems
ATCC
Moderator
Rebecca Bradford, MBA, MS, PMP
Senior Vice President, ATCC Federal Solutions
ATCC
Note: You do not need to be registered for the MPS World Summit to attend this event. Please register using the following form if you are NOT attending the MPS World Summit and would like to attend this event. Summit attendees should register through the conference website: https://mpsworldsummit.org/2026-registration-information/
Attend our presentation
Beyond Animal Models: Precision Oncology Begins with Human-Derived 3-D Models
Date: May 27, 2026 | Time: 12:45–1:45 PM | Location: Walter E. Washington Convention Center (Room 203B)
Join our presentation to explore how patient-derived cancer organoids from the HCMI are advancing precision oncology by capturing tumor complexity, heterogeneity, and clinically relevant drug responses. Learn how these well-characterized, data-rich models are enabling predictive drug testing, biomarker discovery, and more inclusive cancer research.
Carolina Lucchesi, PhD
Principal Scientist, Head of Microphysiological Systems, ATCC
Abhay Andar, PhD
Lead Scientist, Microphysiological Systems, ATCC
Shannon Mumenthaler, PhD
Chief Translational Research Officer, Ellison Medical Institute
Associate Professor of Medicine and Biomedical Engineering, USC
Check out our posters
A Human iPSC-derived Neurosphere Model for Studying HIV-1 CNS Infection and Persistence
Presenter: Heather Branscome, PhD, Senior Scientist, ATCC
Date & Time: May 27, 2026, from 3:15 PM – 4:45 PM
Abstract Number: 367
Poster Number: 249
Patient-Derived Organoids (PDOs) for Triple-Negative Breast Cancer: Characterization and Functional Applications
Presenter: Ellie Thamert, MS, Senior Biologist, ATCC
Date & Time: May 28, 2026, from 10:00 AM – 11:30 AM
Abstract Number: 681
Poster Number: 136
Modeling MASLD in a Dynamic Human Liver Microphysiological System
Presenter: Ash Lee Manley, BS, Biologist, ATCC
Date & Time: May 28, 2026, from 10:00 AM – 11:30 AM
Abstract Number: 682
Poster Number: 190
Modeling Tumor–Immune Interactions Using Patient-Derived Lung Organoids on Chip
Presenter: Fernanda Ventura, BS, Biologist, ATCC
Date & Time: May 28, 2026, from 10:00 AM – 11:30 AM
Abstract Number: 684
Poster Number: 138
Explore our featured products
Organoids
During the drug discovery process, having access to models that recapitulate tumor properties is essential for predictive screening. ATCC provides patient-derived 3-D organoid models annotated with molecular and clinical data that represent a variety of healthy and cancerous tissues. These next-generation cancer models are capable of long-term expansion in culture while remaining phenotypically and genetically stable.
Explore patient-derived organoidsOrganoid Growth Kits
In efforts to simplify organoid culture, ATCC has developed Organoid Growth Kits, which comprise single-use supplements created to streamline media preparation. These kits contain the most costly and cumbersome supplements and reagents, reducing the time and effort required to prepare media and ensuring the successful growth of your organoids.
Explore organoid growth kits
Primary human hepatocytes are considered the gold standard for in vitro liver models due to their high predictive value in drug metabolism and toxicity studies. They can provide early insights into how a drug will behave in the human body, potentially reducing the risk of adverse effects in clinical trials. ATCC hepatocytes are meticulously isolated and characterized to ensure the highest quality and performance for your drug development and toxicity testing needs. Try our HepatoXcell™ primary human hepatocytes and media today!
Learn moreCheck out our resources
Exploring the performance of HepatoXcell in a variety of culture formats
In this application note, we demonstrate that the HepatoXcell™ system supports diverse culture formats, offering flexibility for tailoring experimental setups for liver biology research, disease modeling, drug discovery, and toxicity testing.
More
Brochure
Human Cancer Models Initiative (HCMI)
ATCC offers a growing collection of models generated by the HCMI, which will include both common as well as rare and understudied examples of cancer from numerous tissues
MorePrimary Human Hepatocytes
Discover how HepatoXcell™ can support your predictive drug development and toxicity testing.
MoreContact us today
Your ATCC sales representative stands ready to discuss your research needs and provide you with personalized care. Please complete our form to let us know how we can help, and we will start working on your needs right away.
